Corporate Magazine 2012 - Boehringer Ingelheim

More documents

Recommendations

Info

product portfolio70 [ branded prescription medicines ]70 RESPIRATORY DISEASES72 DISEASES OF THE CENTRAL NERVOUS SYSTEM74 CARDIOVASCULAR DISEASES78 METABOLIC DISEASES78 INFECTIOUS DISEASES80 [ consumer health care ]80 COUGH AND COLD80 SORE THROAT82 GASTROINTESTINAL DISEASES84 VITAMINS AND SUPPLEMENTS84 UROLOGICAL DISEASES86 LEG VEIN HEALTH86 PAIN88 [ animal health ]88 FOOD PRODUCING ANIMALS – SWINE88 FOOD PRODUCING ANIMALS – POULTRY90 FOOD PRODUCING ANIMALS – CATTLE92 COMPANION ANIMALS – HORSE94 COMPANION ANIMALS – SMALL ANIMALSCONTENT
Boehringer Ingelheim groupFINANCIAL HIGHLIGHTSAmounts in millions of EUR, unless otherwise indicated 2012 2011 ChangeNet sales 14,691 13,171 12%by regionEurope 29% 31%Americas 47% 46%Asia, Australasia, Africa 24% 23%by businessHuman Pharmaceuticals 93% 93%Animal Health 7% 7%Research and development 2,795 2,516 11%Personnel costs 4,024 3,664 10%Average number of employees 46,228 44,094 5%Operating income 1,853 2,272 — 18%Operating income as % of net sales 12.6% 17.3%Income after taxes 1,237 1,476 — 16%Income after taxes as % of net sales 8.4% 11.2%Shareholders‘ equity 6,178 7,466 — 17%Return on shareholders‘ equity 16.6% 22.8%Cash flow 2,225 2,378 — 6%Investments in tangible assets 562 458 23%Depreciation of tangible assets 793 535 48%Top 4 products — Prescription MedicinesNet sales 2012 in millions of EUR changespiriva® 3,562 + 13%micardis® 1,623 + 2%pradaxa® 1,108 + 76%combivent® 883 + 15%Top 4 products — Consumer Health CareNet sales 2012 in millions of EUR changebuscopan® 212 + 18%dulcolax® 193 + 13%mucosolvan® 166 + 4%pharmaton® 136 – 1%
Page 1 and 2:
Value through InnovationCorporate M
Page 3 and 4:
our businesses66 [ prescription med
Page 7:
value through innovationperspective
Page 10 and 11:
56° 40' 59" N, 5° 6' 14" Wglencoe
Page 12 and 13:
56° 40' 59" N, 5° 6' 14" Wglencoe
Page 14 and 15:
PERSPECTIVES FORSOCIETYIn all our a
Page 16 and 17:
50 NATIONSPeople from around 50 nat
Page 18 and 19:
“RLDP journey: a great learning o
Page 20 and 21:
SHONA MCDONALD, SHONAQUIP[ south af
Page 22 and 23:
SEHNAZ LAYIKEL, RUSIHAK[ turkey ]he
Page 24 and 25:
Thalita Guimaraes joins the “Boeh
Page 26 and 27:
When handling chemicals, employees
Page 28 and 29:
11 With its own wastewater treatmen
Page 30 and 31:
21 Dr Carolyn R. Bertozzi received
Page 32 and 33:
PERSPECTIVES FOR THE SOCIETYOF TOMO
Page 34 and 35:
The opening ceremony of IMB:Interac
Page 36 and 37:
CIRCUIT MECHANICS OF EMOTIONSUnders
Page 38 and 39:
BIBERACH UNIVERSITY OF APPLIEDSCIEN
Page 40 and 41:
22° 41' 0" S, 14° 32' 0" Eswakopm
Page 42 and 43:
22° 41' 0" S, 14° 32' 0" Eswakopm
Page 44 and 45:
PERSPECTIVES FORMEDICAL INNOVATIONB
Page 46 and 47:
RESEARCH PARTNERSHIPS WITHACADEMIA
Page 48 and 49:
collaborate innovate accelerateTRAN
Page 50 and 51:
GLORIA-AF®Registry programme for p
Page 52 and 53:
BOEHRINGER INGELHEIM ONCOLOGY FRANC
Page 54 and 55:
AFATINIB BLOCKS THE ERBB RECEPTORSE
Page 56 and 57:
HEPTATIS C VIRUS (HCV) INFECTIONHCV
Page 58 and 59:
1viral entryrnareleasernatranslated
Page 60 and 61:
12THE MAIN COMPLICATIONS OF DIABETE
Page 62 and 63:
ASTHMAAsthma is a chronic disease c
Page 64 and 65:
THERAPEUTIC AREA (TA) REVIEW CORE T
Page 66 and 67:
6° 59' 15" N, 125° 16' 15" Eapo,
Page 68 and 69:
icardo f. solitariadistrict manager
Page 70 and 71:
PERSPECTIVES FORBETTER HEALTHBoehri
Page 72 and 73:
“My photo shows Frau Röhrigfrom
Page 74 and 75:
OUR CARDIOVASCULAR PORTFOLIOaggreno
Page 76 and 77:
HOW ATRIAL FIBRILLATION (AF)LEADS T
Page 78 and 79:
FINDING THE RIGHT MOLECULE“Findin
Page 80 and 81:
PATIENTS AT CARDIOVASCULAR RISKMost
Page 82 and 83:
TRAJENTA® / TRADJENTA®trajenta®
Page 84 and 85:
WORLD DIABETES DAYWorld Diabetes Da
Page 86 and 87:
SPIRIVA®: 10 YEARS AND MORE OF CLI
Page 88 and 89:
BEHAVIOUR CHANGE INTYPE 2 DIABETEST
Page 90 and 91:
Rapid progress in global healthcare
Page 92 and 93: KEY GOALS OF GLOBAL BUSINESS SERVIC
Page 94 and 95: “The perspectives that open upune
Page 96 and 97: OUR GLOBAL SWITCH TEAMThe Switch un
Page 98 and 99: “For me, the photo shows thatthe
Page 100 and 101: 2 Disposable single use bioreactorw
Page 102 and 103: “The hard-working beessuccessfull
Page 104 and 105: “There are many things and experi
Page 106 and 107: OUR GLOBAL SCIENTIFIC NET WORKIN AN
Page 108 and 109: 2 31 Scientists in Hannover working
Page 110 and 111: “Living and working on a differen
Page 112 and 113: 1 Phoenix, the first captive-bredOr
Page 114 and 115: 55° 21' 0" N, 131° 40' 24" Wketch
Page 116 and 117: scott zhangstrategic effectiveness
Page 118 and 119: PERSPECTIVES FORQUALITY IN OPERATIO
Page 120 and 121: With the quality risk management sy
Page 122 and 123: In order to ensure patient safety,
Page 124 and 125: 37° 34' 48" N, 14° 16' 34" Esicil
Page 126 and 127: 37° 34' 48" N, 14° 16' 34" Esicil
Page 128 and 129: PERSPECTIVES FORESTABLISHED MARKETS
Page 130 and 131: Spain is one of the countries struc
Page 132 and 133: 21 View of Athens.2 Production site
Page 134 and 135: 1 View of San Francisco, the leadin
Page 136 and 137: 211 View of Tokyo with Japan’s hi
Page 138 and 139: IF YOU HAVE ANY QUERIES OR COMMENTS
Page 140 and 141: Value through InnovationBusiness Ye
Page 144 and 145: usiness year 2012our companyOUR COM
Page 146 and 147: usiness year 2012the shareholders
Page 148 and 149: usiness year 2012the shareholders
Page 150 and 151: usiness year 2012 key aspects 2012S
Page 152 and 153: usiness year 2012 key aspects 2012F
Page 154 and 155: usiness year 2012 key aspects 2012B
Page 156 and 157: usiness year 2012corporate bodiesCO
Page 158 and 159: usiness year 2012group management r
Page 178 and 179: usiness year 2012consolidated finan
Page 192 and 193:
usiness year 2012consolidated finan
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
usiness year 2012auditor’s report
Page 208 and 209:
product portfolioa selection2012PRO
Page 210 and 211:
product portfoliobranded prescripti
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
product portfolioconsumer health ca
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
product portfolioanimal healthIndic
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
usiness year 2012financial data2006
Page 238:
www.boehringer-ingelheim.comannualr
show all

Corporate Magazine 2012 - Boehringer Ingelheim

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?